Prime-boost immunization strategies against Chikungunya virus

Journal of Virology

Volumn 88, Issue 22, 2014, Pages 13333-13343

  Hallengärd, David ^a   Lum, Fok Moon ^b,c   Kümmerer, Beate M ^d   Lulla, Aleksei ^e   Lulla, Valeria ^e   García Arriaza, Juan ^f   Fazakerley, John K ^g   Roques, Pierre ^h,i   Grand, Roger Le ^h   Merits, Andres ^e   Ng, Lisa F P ^b,c   Esteban, Mariano ^f   Liljeström, Peter ^a  

^a KAROLINSKA INSTITUTE   (Sweden)

^b AGENCY FOR SCIENCE   (Singapore)

^c NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

^d UNIVERSITY OF BONN   (Germany)

^e UNIVERSITY OF TARTU   (Estonia)

^f CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

^g INSTITUTE FOR ANIMAL HEALTH   (United Kingdom)

^h DIF   (France)

ⁱ UNIVERSITÉ PARIS SACLAY   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CHIKUNGUNYA VIRUS VACCINE; DNA VACCINE; EPITOPE; GAMMA INTERFERON; IMMUNOGLOBULIN G ANTIBODY; IMMUNOLOGICAL ADJUVANT; MODIFIED VACCINIA VIRUS ANKARA CHIKUNGUNYA VIRUS VACCINE; P62 E1 PROTEIN; UNCLASSIFIED DRUG; VIRUS ANTIBODY; VIRUS ANTIGEN; VIRUS VACCINE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBODY RESPONSE; ARTICLE; B LYMPHOCYTE; CELLULAR IMMUNITY; CHIKUNGUNYA; CHIKUNGUNYA ALPHAVIRUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG EFFICACY; FEMALE; IMMUNIZATION; IMMUNOGENICITY; IMMUNOSTIMULATION; INFECTION PREVENTION; MOUSE; NONHUMAN; PRIME BOOST IMMUNIZATION; QUALITATIVE ANALYSIS; REPLICON; SINGLE DRUG DOSE; T LYMPHOCYTE; VIREMIA; ANIMAL; BLOOD; C57BL MOUSE; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODEL; IMMUNOLOGY; MONONUCLEAR CELL; PROCEDURES; SURVIVAL ANALYSIS;

ANIMALS; ANTIBODIES, VIRAL; CHIKUNGUNYA FEVER; CHIKUNGUNYA VIRUS; DISEASE MODELS, ANIMAL; FEMALE; IMMUNIZATION; LEUKOCYTES, MONONUCLEAR; MICE, INBRED C57BL; SURVIVAL ANALYSIS; VACCINES, DNA; VIRAL VACCINES;

EID: 84908388228     PISSN: 0022538X     EISSN: 10985514     Source Type: Journal    
DOI: 10.1128/JVI.01926-14     Document Type: Article

References (68)

1. Her Z, Kam YW, Lin RT, Ng LF. 2009. Chikungunya: a bending reality. Microbes Infect. 11:1165-1176. http://dx.doi.org/10.1016/j.micinf.2009.09.004.
2. Burt FJ, Rolph MS, Rulli NE, Mahalingam S, Heise MT. 2012. Chikungunya: a re-emerging virus. Lancet 379:662-671. http://dx.doi.org/10.1016/S0140-6736(11)60281-X.
3. Van Bortel W, Dorleans F, Rosine J, Blateau A, Rousset D, Matheus S, Leparc-Goffart I, Flusin O, Prat C, Cesaire R, Najioullah F, Ardillon V, Balleydier E, Carvalho L, Lemaitre A, Noel H, Servas V, Six C, Zurbaran M, Leon L, Guinard A, van den Kerkhof J, Henry M, Fanoy E, Braks M, Reimerink J, Swaan C, Georges R, Brooks L, Freedman J, Sudre B, Zeller H. 3 April 2014. Chikungunya outbreak in the Caribbean region, December 2013 to March 2014, and the significance for Europe. Euro Surveill. 19(13):pii 20759. http://www.eurosurveillance.org/ViewArticle.aspx?ArticleId=20759.
4. Schwartz O, Albert ML. 2010. Biology and pathogenesis of chikungunya virus. Nat. Rev. Microbiol. 8:491-500. http://dx.doi.org/10.1038/nrmicro2368.
5. Vijayakumar KP, Nair Anish TS, George B, Lawrence T, Muthukkutty SC, Ramachandran R. 2011. Clinical profile of Chikungunya patients during the epidemic of 2007 in Kerala, India. J. Glob. Infect. Dis. 3:221-226. http://dx.doi.org/10.4103/0974-777X.83526.
6. Couturier E, Guillemin F, Mura M, Leon L, Virion JM, Letort MJ, De Valk H, Simon F, Vaillant V. 2012. Impaired quality of life after chikungunya virus infection: a 2-year follow-up study. Rheumatology (Oxford) 51:1315-1322. http://dx.doi.org/10.1093/rheumatology/kes015.
7. Essackjee K, Goorah S, Ramchurn SK, Cheeneebash J, Walker-Bone K. 2013. Prevalence of and risk factors for chronic arthralgia and rheumatoid-like polyarthritis more than 2 years after infection with chikungunya virus. Postgrad. Med. J. 89:440-447. http://dx.doi.org/10.1136/postgradmedj-2012-131477.
8. Mavalankar D, Shastri P, Bandyopadhyay T, Parmar J, Ramani KV. 2008. Increased mortality rate associated with chikungunya epidemic, Ahmedabad, India. Emerg. Infect. Dis. 14:412-415. http://dx.doi.org/10.3201/eid1403.070720.
9. Weaver SC, Osorio JE, Livengood JA, Chen R, Stinchcomb DT. 2012. Chikungunya virus and prospects for a vaccine. Expert Rev. Vaccines 11: 1087-1101. http://dx.doi.org/10.1586/erv.12.84.
10. Chu H, Das SC, Fuchs JF, Suresh M, Weaver SC, Stinchcomb DT, Partidos CD, Osorio JE. 2013. Deciphering the protective role of adaptive immunity to CHIKV/IRES a novel candidate vaccine against Chikungunya in the A129 mouse model. Vaccine 31:3353-3360. http://dx.doi.org/10.1016/j.vaccine.2013.05.059.
11. Edelman R, Tacket CO, Wasserman SS, Bodison SA, Perry JG, Mangiafico JA. 2000. Phase II safety and immunogenicity study of live chikungunya virus vaccine TSI-GSD-218. Am. J. Trop. Med. Hyg. 62:681-685.
12. Hallengärd D, Kakoulidou M, Lulla A, Kummerer BM, Johansson DX, Mutso M, Lulla V, Fazakerley JK, Roques P, Le Grand R, Merits A, Liljeström P. 2014. Novel attenuated Chikungunya vaccine candidates elicit protective immunity in C57BL/6 mice. J. Virol. 88:2858-2866. http://dx.doi.org/10.1128/JVI.03453-13.
13. Levitt NH, Ramsburg HH, Hasty SE, Repik PM, Cole FE, Jr, Lupton HW. 1986. Development of an attenuated strain of chikungunya virus for use in vaccine production. Vaccine 4:157-162. http://dx.doi.org/10.1016/0264-410X(86)90003-4.
14. Partidos CD, Paykel J, Weger J, Borland EM, Powers AM, Seymour R, Weaver SC, Stinchcomb DT, Osorio JE. 2012. Cross-protective immunity against o'nyong-nyong virus afforded by a novel recombinant chikungunya vaccine. Vaccine 30:4638-4643. http://dx.doi.org/10.1016/j.vaccine.2012.04.099.
15. Piper A, Ribeiro M, Smith KM, Briggs CM, Huitt E, Nanda K, Spears CJ, Quiles M, Cullen J, Thomas ME, Brown DT, Hernandez R. 2013. Chikungunya virus host range E2 transmembrane deletion mutants induce protective immunity against challenge in C57BL/6J mice. J. Virol. 87:6748-6757. http://dx.doi.org/10.1128/JVI.03357-12.
16. Plante K, Wang E, Partidos CD, Weger J, Gorchakov R, Tsetsarkin K, Borland EM, Powers AM, Seymour R, Stinchcomb DT, Osorio JE, Frolov I, Weaver SC. 2011. Novel chikungunya vaccine candidate with an IRES-based attenuation and host range alteration mechanism. PLoS Pathog. 7:e1002142. http://dx.doi.org/10.1371/journal.ppat.1002142.
17. Harrison VR, Eckels KH, Bartelloni PJ, Hampton C. 1971. Production and evaluation of a formalin-killed Chikungunya vaccine. J. Immunol. 107:643-647.
18. Tiwari M, Parida M, Santhosh SR, Khan M, Dash PK, Rao PV. 2009. Assessment of immunogenic potential of Vero adapted formalin inactivated vaccine derived from novel ECSA genotype of Chikungunya virus. Vaccine 27:2513-2522. http://dx.doi.org/10.1016/j.vaccine.2009.02.062.
19. White A, Berman S, Lowenthal JP. 1972. Comparative immunogenicities of Chikungunya vaccines propagated in monkey kidney monolayers and chick embryo suspension cultures. Appl. Microbiol. 23:951-952.
20. Chattopadhyay A, Wang E, Seymour R, Weaver SC, Rose JK. 2013. A chimeric vesiculo/alphavirus is an effective alphavirus vaccine. J. Virol. 87:395-402. http://dx.doi.org/10.1128/JVI.01860-12.
21. Wang D, Suhrbier A, Penn-Nicholson A, Woraratanadharm J, Gardner J, Luo M, Le TT, Anraku I, Sakalian M, Einfeld D, Dong JY. 2011. A complex adenovirus vaccine against chikungunya virus provides complete protection against viraemia and arthritis. Vaccine 29:2803-2809. http://dx.doi.org/10.1016/j.vaccine.2011.01.108.
22. Wang E, Volkova E, Adams AP, Forrester N, Xiao SY, Frolov I, Weaver SC. 2008. Chimeric alphavirus vaccine candidates for chikungunya. Vaccine 26:5030-5039. http://dx.doi.org/10.1016/j.vaccine.2008.07.054.
23. Akahata W, Yang ZY, Andersen H, Sun S, Holdaway HA, Kong WP, Lewis MG, Higgs S, Rossmann MG, Rao S, Nabel GJ. 2010. A virus-like particle vaccine for epidemic Chikungunya virus protects nonhuman primates against infection. Nat. Med. 16:334-338. http://dx.doi.org/10.1038/nm.2105.
24. Kumar M, Sudeep AB, Arankalle VA. 2012. Evaluation of recombinant E2 protein-based and whole-virus inactivated candidate vaccines against chikungunya virus. Vaccine 30:6142-6149. http://dx.doi.org/10.1016/j.vaccine.2012.07.072.
25. Metz SW, Gardner J, Geertsema C, Le TT, Goh L, Vlak JM, Suhrbier A, Pijlman GP. 2013. Effective chikungunya virus-like particle vaccine produced in insect cells. PLoS Negl. Trop. Dis. 7:e2124. http://dx.doi.org/10.1371/journal.pntd.0002124.
26. Metz SW, Geertsema C, Martina BE, Andrade P, Heldens JG, van Oers MM, Goldbach RW, Vlak JM, Pijlman GP. 2011. Functional processing and secretion of Chikungunya virus E1 and E2 glycoproteins in insect cells. Virol. J. 8:353. http://dx.doi.org/10.1186/1743-422X-8-353.
27. Metz SW, Martina BE, van den Doel P, Geertsema C, Osterhaus AD, Vlak JM, Pijlman GP. 2013. Chikungunya virus-like particles are more immunogenic in a lethal AG129 mouse model compared to glycoprotein E1 or E2 subunits. Vaccine 31:6092-6096. http://dx.doi.org/10.1016/j.vaccine.2013.09.045.
28. Brandler S, Ruffie C, Combredet C, Brault JB, Najburg V, Prevost MC, Habel A, Tauber E, Despres P, Tangy F. 2013. A recombinant measles vaccine expressing chikungunya virus-like particles is strongly immunogenic and protects mice from lethal challenge with chikungunya virus. Vaccine 31:3718-3725. http://dx.doi.org/10.1016/j.vaccine.2013.05.086.
29. García-Arriaza J, Cepeda V, Hallengard D, Sorzano CO, Kummerer BM, Liljeström P, Esteban M. 2014. A novel poxvirus-based vaccine, MVA-CHIKV, is highly immunogenic and protects mice against Chikungunya infection. J. Virol. 88:3527-3547. http://dx.doi.org/10.1128/JVI.03418-13.
30. Mallilankaraman K, Shedlock DJ, Bao H, Kawalekar OU, Fagone P, Ramanathan AA, Ferraro B, Stabenow J, Vijayachari P, Sundaram SG, Muruganandam N, Sarangan G, Srikanth P, Khan AS, Lewis MG, Kim JJ, Sardesai NY, Muthumani K, Weiner DB. 2011. A DNA vaccine against chikungunya virus is protective in mice and induces neutralizing antibodies in mice and nonhuman primates. PLoS Negl. Trop. Dis. 5:e928. http://dx.doi.org/10.1371/journal.pntd.0000928.
31. Muthumani K, Lankaraman KM, Laddy DJ, Sundaram SG, Chung CW, Sako E, Wu L, Khan A, Sardesai N, Kim JJ, Vijayachari P, Weiner DB. 2008. Immunogenicity of novel consensus-based DNA vaccines against Chikungunya virus. Vaccine 26:5128-5134. http://dx.doi.org/10.1016/j.vaccine.2008.03.060.
32. Barry G, Fragkoudis R, Ferguson MC, Lulla A, Merits A, Kohl A, Fazakerley JK. 2010. Semliki Forest virus-induced endoplasmic reticulum stress accelerates apoptotic death of mammalian cells. J. Virol. 84:7369-7377. http://dx.doi.org/10.1128/JVI.02310-09.
33. Glasgow GM, McGee MM, Sheahan BJ, Atkins GJ. 1997. Death mechanisms in cultured cells infected by Semliki Forest virus. J. Gen. Virol. 78(Part 7):1559-1563.
34. Hidmark AS, McInerney GM, Nordstrom EK, Douagi I, Werner KM, Liljeström P, Karlsson Hedestam GB. 2005. Early alpha/beta interferon production by myeloid dendritic cells in response to UVinactivated virus requires viral entry and interferon regulatory factor 3 but not MyD88. J. Virol. 79:10376-10385. http://dx.doi.org/10.1128/JVI.79.16.10376-10385.2005.
35. Berglund P, Smerdou C, Fleeton MN, Tubulekas I, Liljeström P. 1998. Enhancing immune responses using suicidal DNA vaccines. Nat. Biotechnol. 16:562-565. http://dx.doi.org/10.1038/nbt0698-562.
36. Knudsen ML, Mbewe-Mvula A, Rosario M, Johansson DX, Kakoulidou M, Bridgeman A, Reyes-Sandoval A, Nicosia A, Ljungberg K, Hanke T, Liljeström P. 2012. Superior induction of T cell responses to conserved HIV-1 regions by electroporated alphavirus replicon DNA compared to that with conventional plasmid DNA vaccine. J. Virol. 86:4082-4090. http://dx.doi.org/10.1128/JVI.06535-11.
37. Nordström EK, Forsell MN, Barnfield C, Bonin E, Hanke T, Sundstrom M, Karlsson GB, Liljeström P. 2005. Enhanced immunogenicity using an alphavirus replicon DNA vaccine against human immunodeficiency virus type 1. J. Gen. Virol. 86:349-354. http://dx.doi.org/10.1099/vir.0.80481-0.
38. Dubensky TW, Jr, Driver DA, Polo JM, Belli BA, Latham EM, Ibanez CE, Chada S, Brumm D, Banks TA, Mento SJ, Jolly DJ, Chang SM. 1996. Sindbis virus DNA-based expression vectors: utility for in vitro and in vivo gene transfer. J. Virol. 70:508-519.
39. Hariharan MJ, Driver DA, Townsend K, Brumm D, Polo JM, Belli BA, Catton DJ, Hsu D, Mittelstaedt D, McCormack JE, Karavodin L, Dubensky TW, Jr, Chang SM, Banks TA. 1998. DNA immunization against herpes simplex virus: enhanced efficacy using a Sindbis virusbased vector. J. Virol. 72:950-958.
40. Ljungberg K, Whitmore AC, Fluet ME, Moran TP, Shabman RS, Collier ML, Kraus AA, Thompson JM, Montefiori DC, Beard C, Johnston RE. 2007. Increased immunogenicity of a DNA-launched Venezuelan equine encephalitis virus-based replicon DNA vaccine. J. Virol. 81:13412-13423. http://dx.doi.org/10.1128/JVI.01799-07.
41. Lu S. 2009. Heterologous prime-boost vaccination. Curr. Opin. Immunol. 21:346-351. http://dx.doi.org/10.1016/j.coi.2009.05.016.
42. Voss JE, Vaney MC, Duquerroy S, Vonrhein C, Girard-Blanc C, Crublet E, Thompson A, Bricogne G, Rey FA. 2010. Glycoprotein organization of Chikungunya virus particles revealed by X-ray crystallography. Nature 468:709-712. http://dx.doi.org/10.1038/nature09555.
43. Pohjala L, Utt A, Varjak M, Lulla A, Merits A, Ahola T, Tammela P. 2011. Inhibitors of alphavirus entry and replication identified with a stable Chikungunya replicon cell line and virus-based assays. PLoS One 6:e28923. http://dx.doi.org/10.1371/journal.pone.0028923.
44. Roos AK, Eriksson F, Timmons JA, Gerhardt J, Nyman U, Gudmundsdotter L, Bråve A, Wahren B, Pisa P. 2009. Skin electroporation: effects on transgene expression, DNA persistence and local tissue environment. PLoS One 4:e7226. http://dx.doi.org/10.1371/journal.pone.0007226.
45. Gläsker S, Lulla A, Lulla V, Couderc T, Drexler JF, Liljeström P, Lecuit M, Drosten C, Merits A, Kümmerer BM. 2013. Virus replicon particle based Chikungunya virus neutralization assay using Gaussia luciferase as readout. Virol. J. 10:235. http://dx.doi.org/10.1186/1743-422X-10-235.
46. Kam YW, Lee WW, Simarmata D, Harjanto S, Teng TS, Tolou H, Chow A, Lin RT, Leo YS, Renia L, Ng LF. 2012. Longitudinal analysis of the human antibody response to Chikungunya virus infection: implications for serodiagnosis and vaccine development. J. Virol. 86:13005-13015. http://dx.doi.org/10.1128/JVI.01780-12.
47. Kam YW, Lee WW, Simarmata D, Le Grand R, Tolou H, Merits A, Roques P, Ng LF. 2014. Unique epitopes recognized by antibodies induced in chikungunya virus-infected non-human primates: implications for the study of immunopathology and vaccine development. PLoS One 9:e95647. http://dx.doi.org/10.1371/journal.pone.0095647.
48. Kam YW, Lum FM, Teo TH, Lee WW, Simarmata D, Harjanto S, Chua CL, Chan YF, Wee JK, Chow A, Lin RT, Leo YS, Le Grand R, Sam IC, Tong JC, Roques P, Wiesmuller KH, Renia L, Rotzschke O, Ng LF. 2012. Early neutralizing IgG response to Chikungunya virus in infected patients targets a dominant linear epitope on the E2 glycoprotein. EMBO Mol. Med. 4:330-343. http://dx.doi.org/10.1002/emmm.201200213.
49. Lum FM, Teo TH, Lee WW, Kam YW, Renia L, Ng LF. 2013. An essential role of antibodies in the control of chikungunya virus infection. J. Immunol. 190:6295-6302. http://dx.doi.org/10.4049/jimmunol.1300304.
50. Kam YW, Simarmata D, Chow A, Her Z, Teng TS, Ong EK, Renia L, Leo YS, Ng LF. 2012. Early appearance of neutralizing immunoglobulin G3 antibodies is associated with chikungunya virus clearance and longterm clinical protection. J. Infect. Dis. 205:1147-1154. http://dx.doi.org/10.1093/infdis/jis033.
51. Pettersen EF, Goddard TD, Huang CC, Couch GS, Greenblatt DM, Meng EC, Ferrin TE. 2004. UCSF Chimera-a visualization system for exploratory research and analysis. J. Comput. Chem. 25:1605-1612. http://dx.doi.org/10.1002/jcc.20084.
52. Magnusson SE, Reimer JM, Karlsson KH, Lilja L, Bengtsson KL, Stertman L. 2013. Immune enhancing properties of the novel Matrix-M adjuvant leads to potentiated immune responses to an influenza vaccine in mice. Vaccine 31:1725-1733. http://dx.doi.org/10.1016/j.vaccine.2013.01.039.
53. Gilca V, De Serres G, Hamelin ME, Boivin G, Ouakki M, Boulianne N, Sauvageau C, Dionne M, Gilca R, Skowronski D. 2011. Antibody persistence and response to 2010-2011 trivalent influenza vaccine one year after a single dose of 2009 AS03-adjuvanted pandemic H1N1 vaccine in children. Vaccine 30:35-41. http://dx.doi.org/10.1016/j.vaccine.2011.10.062.
54. Akahata W, Nabel GJ. 2012. A specific domain of the Chikungunya virus E2 protein regulates particle formation in human cells: implications for alphavirus vaccine design. J. Virol. 86:8879-8883. http://dx.doi.org/10.1128/JVI.00370-12.
55. Gardner CL, Hritz J, Sun C, Vanlandingham DL, Song TY, Ghedin E, Higgs S, Klimstra WB, Ryman KD. 2014. Deliberate attenuation of chikungunya virus by adaptation to heparan sulfate-dependent infectivity: a model for rational arboviral vaccine design. PLoS Negl. Trop. Dis. 8:e2719. http://dx.doi.org/10.1371/journal.pntd.0002719.
56. McKay PF, Cope AV, Mann JF, Joseph S, Esteban M, Tatoud R, Carter D, Reed SG, Weber J, Shattock RJ. 2014. Glucopyranosyl lipid A adjuvant significantly enhances HIV specific T and B cell responses elicited by a DNA-MVA-protein vaccine regimen. PLoS One 9:e84707. http://dx.doi.org/10.1371/journal.pone.0084707.
57. Gardner J, Anraku I, Le TT, Larcher T, Major L, Roques P, Schroder WA, Higgs S, Suhrbier A. 2010. Chikungunya virus arthritis in adult wild-type mice. J. Virol. 84:8021-8032. http://dx.doi.org/10.1128/JVI.02603-09.
58. Coffey LL, Vignuzzi M. 2011. Host alternation of chikungunya virus increases fitness while restricting population diversity and adaptability to novel selective pressures. J. Virol. 85:1025-1035. http://dx.doi.org/10.1128/JVI.01918-10.
59. Hughes HR, Crill WD, Chang GJ. 2012. Manipulation of immunodominant dengue virus E protein epitopes reduces potential antibodydependent enhancement. Virol. J. 9:115. http://dx.doi.org/10.1186/1743-422X-9-115.
60. + T cells in immunity to viruses. Nat. Rev. Immunol. 12:136-148. http://dx.doi.org/10.1038/nri3152.
61. Plotkin SA. 2013. Complex correlates of protection after vaccination. Clin. Infect. Dis. 56:1458-1465. http://dx.doi.org/10.1093/cid/cit048.
62. Holzer GW, Coulibaly S, Aichinger G, Savidis-Dacho H, Mayrhofer J, Brunner S, Schmid K, Kistner O, Aaskov JG, Falkner FG, Ehrlich H, Barrett PN, Kreil TR. 2011. Evaluation of an inactivated Ross River virus vaccine in active and passive mouse immunization models and establishment of a correlate of protection. Vaccine 29:4132-4141. http://dx.doi.org/10.1016/j.vaccine.2011.03.089.
63. Suhrbier A, Jaffar-Bandjee MC, Gasque P. 2012. Arthritogenic alphaviruses- an overview. Nat. Rev. Rheumatol. 8:420-429. http://dx.doi.org/10.1038/nrrheum.2012.64.
64. Kreil TR, Eibl MM. 1997. Pre-and postexposure protection by passive immunoglobulin but no enhancement of infection with a flavivirus in a mouse model. J. Virol. 71:2921-2927.
65. Lidbury BA, Mahalingam S. 2000. Specific ablation of antiviral gene expression in macrophages by antibody-dependent enhancement of Ross River virus infection. J. Virol. 74:8376-8381. http://dx.doi.org/10.1128/JVI.74.18.8376-8381.2000.
66. Lobigs M, Larena M, Alsharifi M, Lee E, Pavy M. 2009. Live chimeric and inactivated Japanese encephalitis virus vaccines differ in their crossprotective values against Murray Valley encephalitis virus. J. Virol. 83: 2436-2445. http://dx.doi.org/10.1128/JVI.02273-08.
67. Wallace MJ, Smith DW, Broom AK, Mackenzie JS, Hall RA, Shellam GR, McMinn PC. 2003. Antibody-dependent enhancement of Murray Valley encephalitis virus virulence in mice. J. Gen. Virol. 84:1723-1728. http://dx.doi.org/10.1099/vir.0.18980-0.
68. Plotkin SA, Gilbert PB. 2012. Nomenclature for immune correlates of protection after vaccination. Clin. Infect. Dis. 54:1615-1617. http://dx.doi.org/10.1093/cid/cis238.